Objective: Endovascular aneurysm repair (EVAR) has reduced perioperative mortality for patients undergoing abdominal aortic aneurysm (AAA) repair despite the increase in elective aneurysm repair for the elderly. However, Medicare will not cover screening for beneficiaries older than 75 years, and AAA treatment in this population depends on incidental detection. Thus, we risk stratified elderly patients undergoing elective AAA repair to identify a subset of elderly patients who would potentially benefit from an expanded screening policy.
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VESS26. Objective: Vascular graft infection is a devastating and potentially deadly complication with often limited options for revascularization. Physician-prepared polymethyl methacrylate (PMMA) beads have been used to treat infections after orthopedic and soft tissue infections. This technique has been expanded for use in vascular graft salvage. We report our bead preparation and exchange protocol used for vascular graft infections during a 5-year period at our institution.
An
Methods: Between 2013 and 2018, there were 29 patients with vascular graft infections identified. Patients with previous prosthetic patch angioplasty, dialysis access procedures, or lower extremity prosthetic bypass grafts with culture-confirmed evidence of infection were included. PMMA beads were combined with culture-specific antibiotics and prepared by the surgeon at time of implantation. Patients underwent two or three series of wound débridement, pulse lavage, and antibiotic bead placement.
Results: Of the 29 patients treated with antibiotic PMMA beads, we were able to achieve graft salvage in 22 patients (76%). There were 26 patients who had threatened limbs from infections in lower extremity bypass grafts or femoral patch angioplasty site infections. In this group, we achieved limb salvage in 22 patients (85%). Three of the 26 patients (11.5%) at risk for limb loss required a new bypass (two extra-anatomic bypasses and lower extremity vein bypass in situ). One dialysis graft was not salvaged and was replaced.
Conclusions: We report an 85% limb salvage rate and a 76% graft salvage rate in patients with infected vascular grafts during a 5-year period using physician-prepared antibiotic beads. This technique is an important tool for salvaging infected vascular grafts and is an alternative to extra-anatomic bypass, complex or compromised dialysis access options, or amputation. We recommend two or three exchanges of the antibiotic beads with culture-specific antibiotics as available. Objective: Statin therapy and dosing intensity at hospital discharge are associated with higher long-term survival after vascular procedures. Discontinuation of statins and dosing changes are common, but the effect of these changes has yet to be characterized. We evaluated the association between statin intensity and long-term survival 1 year after lower extremity revascularization for chronic limb-threatening ischemia (CLTI).
Methods: We reviewed consecutive patients undergoing first-time endovascular or open revascularization for CLTI at a single institution from 2005 to 2014. We classified statin intensity by the American College of Cardiology/American Heart Association guidelines and evaluated change in statin intensity from discharge to 1-year follow-up. We compared long-term mortality beyond 1 year using Cox regression.
Results: We identified 1336 first-time revascularizations in 1195 patients with CLTI, of which 884 revascularizations in 792 patients had follow-up through 1 year. At 1 year, 165 patients (19%) were not taking a statin, 71 (8.3%) were receiving low-intensity therapy, 403 (47%) were receiving moderate-intensity therapy, and 221 (28%) were receiving high-intensity therapy. From discharge to 1-year follow-up, 101 patients (12%) had never taken a statin, 106 (12%) had their statin stopped or intensity decreased, 134 (16%) had a statin started or intensity increased, and 512 (60%) remained on stable statin therapy. In multivariable analysis, high-and moderate-intensity statin therapy at 1 year was associated with lower mortality compared with no statin therapy (high: hazard ratio [HR], 0.58 [95% confidence interval, 0.39-0.88; P ¼ .01]; moderate: HR, 0.61 [0.42-0.89; P ¼ .01]). There was no difference between low-intensity therapy and no statin therapy (HR, ]; P ¼ .96). Furthermore, stable statin therapy and having a statin started or intensity increased were associated with lower mortality compared with never taking a statin Abstracts
Journal of Vascular Surgery
June 2018
